Acquiring a company with active clinical trials introduces a layer of regulatory obligation that most general M&A frameworks are not built to address. The target's pipeline value rests almost entirely on the continuity and compliance status of those trials, and a sponsor transfer that is handled incorrectly can suspend enrollment, trigger a clinical hold, or introduce safety reporting gaps that FDA scrutinizes for years after closing. This article works through the principal diligence categories and transfer mechanics that counsel must address in any clinical-stage life sciences acquisition.
Trial Master File Diligence Scope
The trial master file is the regulatory backbone of any clinical program. Under ICH E6(R2) Good Clinical Practice guidelines, the TMF must contain all essential documents that demonstrate the sponsor, investigator, and sites maintained proper oversight and conducted the trial in accordance with the protocol and applicable regulations. In an M&A context, the TMF is also the evidentiary record that an acquirer inherits along with every compliance risk embedded in it.
A thorough TMF review begins with the TMF index, which should list every document category required by ICH E6(R2) and map each category to the actual document in the repository. Gaps in the index are immediate flags. Missing or unsigned investigator agreements, absent IRB approval letters, undocumented protocol amendments, and missing adverse event source records all indicate either poor sponsor oversight during the trial or, more concerning, retrospective document reconstruction. Either condition creates regulatory exposure for the acquirer because FDA inspections examine document authenticity, version control, and the temporal relationship between events and their documentation.
Beyond the index, counsel should assess whether the TMF system itself is validated and audit-trail enabled. Electronic TMF platforms must meet 21 CFR Part 11 requirements for electronic records if the sponsor relies on them for regulatory submissions. An unvalidated eTMF, or a hybrid paper-and-electronic system with inconsistent document control, is both a diligence concern and a post-closing remediation project. Acquirers should factor TMF remediation costs into deal modeling and, where gaps are material, negotiate representation and warranty coverage for TMF completeness.
The pre-IND meeting record is a TMF category that receives less attention than it deserves. Pre-IND meeting minutes, type B and type C meeting correspondence, and any written FDA responses are part of the scientific and regulatory history of the program. If an acquirer intends to modify the development strategy post-closing, understanding what FDA has already communicated about the program's design, endpoints, or safety expectations is foundational. Undisclosed pre-IND correspondence that reflects FDA skepticism about a primary endpoint, for example, can materially affect the program's development path and timeline assumptions baked into the valuation.
IND Sponsor Obligations Under 21 CFR 312
The IND holder is the legal sponsor of the clinical program under federal law. 21 CFR 312.50 establishes that the sponsor is responsible for selecting qualified investigators, providing them with the information they need to conduct the investigation properly, ensuring proper monitoring, ensuring that the investigation is conducted in accordance with the general investigational plan and protocols, maintaining an effective IND, and ensuring that FDA and all participating investigators are promptly informed of significant new adverse effects or risks. These are non-delegable in the sense that they attach to the sponsor entity regardless of what operational arrangements the sponsor has in place with CROs or other service providers.
Acquirers must understand that assuming the IND means assuming every one of these obligations, not just the scientific program. A sponsor who has relied heavily on a CRO for monitoring and oversight must confirm in diligence that the CRO agreements transfer cleanly and that the CRO's monitoring records are available and complete. A sponsor who has been operationally inattentive to protocol deviations at certain sites must understand that those deviations are now the acquirer's compliance record. There is no mechanism to disclaim inherited compliance history once the IND transfer is accepted.
The sponsor's financial responsibility for investigator and site obligations under 21 CFR 312.53 is also a diligence category. This regulation requires sponsors to select qualified investigators and obtain signed FDA Form 1572 statements from each. Any site where a Form 1572 was not obtained, was obtained but not updated after a principal investigator change, or reflects a site that is no longer GCP-compliant represents a potential regulatory deficiency that FDA can raise on inspection. Acquirers should confirm that every active site has a current, executed Form 1572 in the TMF before closing.
IND Transfer Letter Mechanics
The procedural mechanism for transferring an IND is straightforward but must be executed correctly. The current sponsor submits a letter to FDA's relevant review division requesting transfer of the IND to the named acquirer entity, accompanied by a statement from the acquirer accepting the IND and all associated obligations. FDA does not approve the transfer in a formal sense; rather, it acknowledges receipt and updates its records. From a regulatory standpoint, the transfer is complete when FDA acknowledges it, not when the letter is submitted.
The timing of the transfer letter relative to closing requires careful coordination. If the transfer letter is submitted before closing and FDA acknowledges it before the transaction closes, the acquirer technically assumes sponsor obligations before it legally owns the company, which creates a gap in indemnification alignment. If the transfer letter is submitted post-closing without a bridging arrangement, the original sponsor entity may no longer exist or may lack the operational capacity to fulfill sponsor obligations during the acknowledgment window. Counsel should structure a transition arrangement under which the original sponsor entity remains nominally responsible for FDA obligations until acknowledgment, with a clear internal indemnification mechanism in favor of the acquirer for any obligations arising during that window.
Where a program has multiple INDs, for example separate INDs for different indications or different patient populations, each IND requires a separate transfer letter. Acquirers sometimes discover in diligence that a target has filed multiple INDs for variations of the same compound without maintaining consistent documentation across all files. Each IND should be diligenced separately, and the transfer mechanics should be confirmed for each before closing.
The transfer also carries with it all prior FDA correspondence, clinical holds, hold releases, agency commitments, and agreed-upon protocol conditions. Acquirers who have not reviewed that correspondence history before accepting the IND inherit any open agency commitments without awareness of them. A condition imposed by FDA as part of a prior hold release, for example a requirement to conduct additional safety monitoring at specified intervals, remains binding on the new sponsor. Diligence on FDA correspondence is not optional; it is a threshold requirement for accurately assessing what program obligations the acquirer is assuming.
CTA Assignment in Ex-US Jurisdictions
For programs with ex-US clinical activity, the complexity of the sponsor transfer scales with the number of jurisdictions involved. In the European Union, the sponsor of a Clinical Trial Application under the EU Clinical Trials Regulation (EU CTR) or the transitional regime under Directive 2001/20/EC must be a legal entity established within the EU or EEA, or must appoint an EU-based legal representative. A US acquirer without an EU legal entity must either establish one or retain a contract research organization to serve as the EU sponsor representative. This is not a formality; the EU sponsor representative assumes regulatory responsibilities that parallel the FDA sponsor role, and gaps in that coverage can result in the national competent authority requiring suspension of enrollment.
In the UK post-Brexit, the MHRA administers the Clinical Trial Authorisation regime independently of the EMA. A CTA transfer to a new sponsor in the UK requires a substantial amendment notification to the MHRA, and the new sponsor must be named explicitly in the CTA. The MHRA's review window for substantial amendments varies, and acquirers should model in a 30 to 60 day acknowledgment window before assuming the transfer is operationally complete. Health Canada's Clinical Trial Application process similarly requires notification of a sponsor change, and the Canadian regulations impose specific requirements for the sponsor's qualified person and adverse event reporting obligations that may differ from what the target had in place.
In jurisdictions where clinical site agreements are governed by local law, the assignability of those agreements depends on the governing law and any explicit consent requirements. Some jurisdictions require site consent before a clinical site agreement can be assigned to a new sponsor entity. Diligence should identify all active sites, their governing law, and the consent mechanics in each agreement. Where consent is required, the acquirer's counsel should begin the consent solicitation process in parallel with regulatory transfer filings to avoid enrollment disruption post-closing.
FDA Form 1572 Updates and Site Compliance
FDA Form 1572, the Statement of Investigator, is the formal commitment by each principal investigator to conduct the clinical trial in accordance with the protocol, GCP, and applicable regulations. The Form 1572 identifies the sponsor, the protocol, and the specific investigator, and it requires the investigator to acknowledge their obligations regarding recordkeeping, adverse event reporting, and IRB oversight. When the sponsor changes, the Form 1572 technically references an entity that no longer holds the IND, which creates a documentation gap that FDA inspectors have cited in warning letters and Form 483 observations.
Best practice requires submitting updated Form 1572 documents to all active investigators reflecting the new sponsor entity, obtaining executed copies, and filing them in the TMF. This is an operational task that requires site coordinator engagement and, in some cases, investigator negotiation where investigators are concerned about their obligations under a new sponsor's oversight approach. Acquirers who delay this process post-closing risk arriving at an FDA inspection with outdated investigator statements. The risk is compounded where principal investigators have changed mid-study and the relevant Form 1572 amendments were not filed in the first instance, a gap that diligence should identify before the acquirer assumes responsibility for remediation.
The Form 1572 update process is also an opportunity to confirm that all active sites remain in good standing. Sites that have experienced significant protocol deviations, that have not been monitored within the required monitoring interval, or that have undergone personnel changes without proper notification are compliance risks that the acquirer should assess before closing. A site that FDA has already placed on a restricted enrollment list due to prior inspection findings is a material finding that affects the trial's enrollment projections and may require remediation before enrollment can continue.
IRB Re-approval Timing and Risk
Every active clinical site conducts its study under the continuing oversight of an institutional review board or independent ethics committee. The IRB's approval covers the specific protocol, the consent documents, and the sponsor as identified in those documents. A sponsor transfer is a material change that most IRBs treat as requiring notification, and many require formal re-review before the new sponsor's oversight relationship is recognized as compliant.
The re-approval timeline is one of the most operationally significant risks in a clinical acquisition. IRBs that meet monthly will have gaps of up to 30 days between review cycles, and complex programs or those with prior deviation histories may require convened (full board) rather than expedited review. Where a program has sites at 30 or 40 institutions, each with its own IRB and review cycle, the acquirer faces a rolling re-approval process that can extend for several months post-closing. During that process, the enrollment status at each site depends on whether the IRB has authorized continued enrollment under the new sponsor.
Acquirers should, in diligence, map every active site's IRB, determine the IRB's notification and re-review requirements, and model the re-approval timeline into enrollment projections. Where milestones are tied to enrollment completion and enrollment completion depends on all sites being active, IRB re-approval delays represent a direct path to missed milestones and contingent value right adjustments. This connection is frequently undermodeled in life sciences deal structures that assume continuity of enrollment without accounting for the regulatory approval cycle at each site.
Investigator Agreements and Compensation Obligations
Each clinical site operates under a clinical trial agreement governing the relationship between the sponsor and the investigator institution. These agreements establish the financial terms of the site's participation, the scope of activities to be performed, the ownership of data generated, publication rights, and the parties' indemnification obligations. In an acquisition, these agreements transfer to the acquirer as part of the assumed contracts, but their content may contain obligations and restrictions that the acquirer has not modeled.
Compensation schedules in clinical site agreements typically specify per-visit payments for enrolled subjects, startup and close-out fees, and sometimes milestone bonuses tied to enrollment targets or protocol completion. The acquirer should audit every executed agreement and its amendments to confirm that the financial terms are accurately reflected in the target's clinical budget model. Sites that are owed amounts for completed visits are immediate post-closing payables. Sites whose payment terms were renegotiated from the original agreement but where the amendment is not in the TMF create a dispute risk.
Investigator agreements also contain publication rights provisions that may restrict the acquirer's ability to control when and how clinical data is published. A provision granting the investigator institution the right to publish after a specified period regardless of sponsor objection is a meaningful constraint on the acquirer's data exclusivity strategy. Where the acquirer's post-closing development plan depends on controlling the timing of scientific publication, these provisions require legal analysis before closing.
Co-investigator arrangements and sub-investigator agreements add another layer of complexity. Where the target has compensated co-investigators through arrangements that involve equity, milestone payments, or royalty interests in the compound, those arrangements may not be reflected in the standard clinical trial agreement review and may require separate legal analysis and potentially renegotiation post-closing.
Adverse Event Reporting Continuity
The sponsor holds primary responsibility for safety reporting under both FDA and ex-US regulatory frameworks. Under 21 CFR 312.32, the sponsor must report unexpected serious adverse events that are associated with use of the investigational drug as expedited 15-day safety reports, and must submit annual safety reports summarizing adverse event experience across all trials. The acquirer, upon assuming the IND, assumes this reporting obligation prospectively and inherits the reporting history retrospectively.
A diligence review of adverse event reporting should confirm that all required expedited reports were submitted on time, that annual safety reports are current, and that the target's MedWatch submission history is complete. Late or missing safety reports are a significant regulatory compliance finding, and FDA has issued warning letters for systematic failures in safety reporting. Acquirers who discover post-closing that the target had unreported or late-reported serious adverse events face both a retroactive reporting obligation and a compliance remediation program.
In the EU, the EudraVigilance database serves as the central repository for adverse event reports under EU CTR and the prior Directive regime. The new sponsor must register with EudraVigilance if not already registered and must ensure that reporting access is transferred appropriately from the target entity. Similarly, safety monitoring agreements with pharmacovigilance vendors must transfer or be replaced with new agreements before closing, as any gap in pharmacovigilance coverage creates a compliance exposure that regulators take seriously.
The acquirer's own pharmacovigilance infrastructure must be capable of absorbing the reporting obligations of the acquired program from day one post-closing. This requires advance planning during the due diligence phase to assess the volume of active safety reports, the status of any ongoing signal evaluations, and the capacity requirements for integrating the program into the acquirer's safety database. Acquirers who lack existing pharmacovigilance infrastructure should engage a contract pharmacovigilance organization pre-closing to ensure coverage from the moment of transfer.
Clinical Supply Chain and CMC Diligence
Active clinical trials consume investigational medicinal product that is manufactured under chemistry, manufacturing, and controls requirements specified in the IND. The CMC section of the IND describes the drug substance and drug product manufacturing processes, the specifications for release testing, and the stability data supporting the proposed shelf life and storage conditions. When the sponsor changes, the manufacturing arrangements underlying the CMC section must continue uninterrupted, and any changes to those arrangements require IND amendments.
Diligence on clinical supply should cover the current manufacturing status of the investigational product: how much finished product is available, what the remaining shelf life is, what the lead time for new manufacturing runs is, and whether the manufacturer is under any regulatory action that would impair its ability to supply. A clinical program that is six months from a protocol milestone but whose drug supply has only three months of remaining shelf life at current enrollment rates is a supply chain risk that directly affects the deal timeline.
Manufacturing agreements with contract manufacturing organizations must be assessed for assignability and transferability. Many CMO agreements contain change-of-control provisions that allow the CMO to terminate or renegotiate terms upon a change in sponsor ownership. Where the CMO is the sole qualified manufacturer for the investigational product, a CMO termination right is a significant leverage point in post-closing negotiations. Acquirers should identify these provisions in diligence and, where necessary, obtain CMO consent or estoppel letters as a closing condition.
Comparator drug supply for controlled trials adds another dimension. Where the protocol requires a comparator drug sourced from a third-party supplier, the supply agreement for the comparator must transfer cleanly and the acquirer must confirm continued availability of the comparator at the volumes required by the ongoing trial. Comparator drug supply disruptions are a common source of trial delays in clinical-stage acquisitions that are not modeled carefully in diligence.
Patient Consent Form Sponsor Reference
Informed consent forms presented to trial participants identify the sponsor by name and provide contact information for safety reporting. When the sponsor changes, every active consent form at every active site references an entity that no longer holds the IND. This is not merely a paperwork issue: the contact information provided for adverse event reporting may no longer be staffed, and participants who experience adverse events and contact the old sponsor entity may not reach the proper safety reporting infrastructure.
FDA's Good Clinical Practice regulations and the Common Rule both require that consent forms provide accurate information about the study, including the sponsor. A post-acquisition obligation therefore exists to update consent forms at all active sites and obtain IRB approval for the updated forms. The timing and process for this update must be coordinated with the IRB re-approval workflow discussed above, as the consent form amendment and the sponsor notification are often reviewed together.
The question of whether previously enrolled participants must re-consent to continue participation under the new sponsor is a site-level and IRB-level determination, but acquirers should be prepared for some IRBs to require affirmative re-consent. Re-consent workflows are operationally intensive, particularly for trials with large enrollment or geographically dispersed sites, and they introduce enrollment disruption risk. Integration plans should assign clear responsibility for consent form updates and establish a tracking mechanism to confirm completion across all sites within a defined post-closing window.
Data Ownership and EDC Transition
Clinical trial data is the primary asset being acquired in many clinical-stage transactions. The integrity, completeness, and accessibility of that data determine whether the program can be submitted to regulatory agencies and whether the acquirer can support the representations made in the transaction about program status. Data diligence should confirm not only that the data exists but that it is owned by the sponsor, stored in a validated system, accessible under the acquirer's control post-closing, and complete through the most recent data lock.
Electronic data capture systems are the repository for most clinical trial data in contemporary drug development. The EDC license is held by the sponsor, and the data rights provisions in the EDC agreement govern what the sponsor can do with the data, including export, migration, and transfer. Acquirers should confirm that the EDC agreement transfers cleanly and that the acquirer's legal entity will have administrative access to the system post-closing. Some EDC vendors treat a change-of-control as a new contract requiring fresh execution and potentially a system migration, which introduces a data accessibility gap if not planned for in advance.
In addition to the EDC, clinical trials generate data in multiple other systems: clinical trial management systems for operational tracking, interactive response technology systems for randomization and drug supply management, central laboratory information systems, and imaging systems for radiographic endpoints. Each system involves a vendor relationship, a data ownership provision, and a transfer or migration requirement. The diligence checklist should map every data system used in the program to its vendor agreement and confirm that the transfer or migration is addressed before closing.
Statistical analysis plan continuity is an extension of the data ownership question. The SAP governs how the primary and secondary efficacy endpoints will be analyzed, and it is typically finalized before unblinding to prevent post-hoc analytical manipulation. Acquirers who seek to modify the SAP post-closing face two constraints: any modification after unblinding is scientifically and regulatorily problematic, and any modification before unblinding requires protocol amendment and potentially re-review. The acquirer should understand the current status of the SAP and whether any planned analytical changes would require regulatory notification before closing.
DSMB and Safety Board Transitions
The data safety monitoring board is an independent body charged with protecting the interests of trial participants by reviewing accumulating safety data at defined intervals and recommending trial continuation, modification, or termination. The DSMB operates under a charter that defines its membership, meeting frequency, access to unblinded data, and the criteria for its recommendations. In a clinical acquisition, the DSMB and its charter transfer as part of the program, but the individual members do not transfer automatically.
Each DSMB member serves under a consulting agreement with the sponsor that specifies the member's compensation, confidentiality obligations, and the scope of their advisory role. When the sponsor changes, those consulting agreements must be formally novated or replaced. Members who are unwilling to continue under the new sponsor create a DSMB composition issue that must be resolved before the next scheduled safety review. A DSMB that does not convene on schedule because its membership is incomplete creates a protocol deviation and, depending on the DSMB charter, may constitute a reportable departure from the safety oversight plan.
The DSMB's access to unblinded data is managed through a statistical analysis center or a contract research organization that serves as the unblinded data source. Transfer of that relationship to the new sponsor must be coordinated to ensure the DSMB's data access is not interrupted. In trials with interim analyses scheduled near the closing date, the timing of the acquisition relative to the DSMB meeting schedule requires careful management to avoid a situation where the DSMB convenes without proper sponsor authorization or without access to complete data.
Where a DSMB has previously issued a recommendation to modify the protocol, reduce enrollment, or enhance safety monitoring, that recommendation creates a binding obligation on the sponsor that transfers with the IND. Acquirers should review all prior DSMB meeting minutes and action items as part of diligence to confirm that all recommendations have been addressed and that no open action items exist at the time of transfer.
Related Resources
Clinical trial diligence sits within a broader framework of life sciences M&A regulatory analysis. Counsel navigating a clinical-stage acquisition should also review the analysis of FDA approval and BLA/NDA transfer mechanics, which addresses the post-Phase III transition from IND to marketing authorization and the regulatory continuity considerations that begin with trial conduct and conclude with agency approval. The contingent value right structuring analysis addresses how clinical milestone uncertainty is allocated between buyers and sellers in life sciences transactions, which is directly relevant to the enrollment and approval milestones that clinical trial status affects. Both are part of the Life Sciences and Pharmaceutical M&A Legal Guide.
- FDA Approval and BLA/NDA Transfer in Pharmaceutical M&A
- Contingent Value Rights in Pharmaceutical M&A: Structuring CVRs for Clinical and Regulatory Milestones
- Life Sciences and Pharmaceutical M&A Legal Guide
Frequently Asked Questions
How long does an IND transfer to the acquirer typically take, and can the trial continue during the process?
An IND transfer under 21 CFR 312 does not follow a fixed regulatory clock, but the mechanics require written notice to FDA, transfer letter submission, and FDA acknowledgment before the acquirer lawfully assumes all sponsor obligations. In practice, FDA typically acknowledges within 30 to 60 days, though complex programs or those with active safety issues can take longer. The existing IND remains in legal effect during the transfer period, meaning the original sponsor entity retains all reporting and oversight obligations until FDA formally accepts the transfer. Acquirers frequently underestimate this gap and should structure closing mechanics to ensure no period exists where no lawful sponsor holds the IND. An experienced M&A counsel will coordinate transfer timing with closing and ensure a bridging arrangement covers any intervening days.
What are the IRB re-approval risks when sponsor identity changes in a clinical acquisition?
IRB re-approval risk is one of the more underappreciated diligence items in clinical-stage acquisitions. Most institutional review boards require notification of a sponsor change, and many require formal re-review of the protocol and consent documents once a new sponsor assumes control. The review timeline varies by institution, and some IRBs operate on monthly meeting cycles that can introduce delays of 30 to 90 days before an amended consent form or protocol is approved. If a trial is enrolling actively, the acquirer must understand whether the IRB will require enrollment suspension pending re-review. Acquirers should audit all site IRB agreements prior to signing, confirm notification requirements, and budget for re-approval timelines that may affect projected enrollment completion dates and, in turn, milestone-linked valuation adjustments.
What does a complete TMF review involve, and what gaps represent material diligence findings?
A trial master file review in the M&A context goes beyond confirming that documents exist. Counsel must assess whether the TMF conforms to ICH E6(R2) GCP guidelines and applicable FDA regulations, whether all essential documents are version-controlled and dated, and whether any regulatory submissions are reflected in the TMF's official record. Material gaps include missing protocol amendments, unsigned investigator agreements, unexecuted financial disclosure forms (FDA Forms 3454 and 3455), absent IRB approval letters, undocumented deviations, and missing adverse event source documentation. A TMF with structural gaps signals either inadequate sponsor oversight or document reconstruction risk post-audit, both of which create regulatory exposure for the acquirer. The diligence process should include a qualified clinical regulatory attorney or consultant conducting a line-by-line TMF index review.
How should acquirers evaluate investigator compensation obligations in clinical-stage deals?
Every site-level clinical trial agreement contains compensation schedules governing per-patient payments, startup fees, and close-out fees. In an acquisition, these agreements transfer to the acquirer along with the IND, but the financial obligations embedded in them may not be fully captured in the target's disclosed liabilities. Diligence should include a complete audit of all executed clinical site agreements and their amendments, with particular attention to per-visit payment schedules, milestone payment triggers, and any renegotiated rates versus what is reflected in the target's clinical budget model. Sites that are owed payments for completed visits or unsponsored costs are a source of post-closing disputes. Additionally, where sites received equity compensation or co-investigator arrangements tied to the original sponsor entity, those arrangements require separate legal review and potentially new agreements post-closing.
What creates clinical hold risk post-acquisition, and how can acquirers mitigate it?
A clinical hold under 21 CFR 312.42 is an FDA order requiring the sponsor to stop enrollment or dosing, and it can be issued at any time including during or shortly after a sponsor transfer. Acquirers inherit not only the program but all prior safety signals, incomplete responses to FDA information requests, and any pending inspection findings. The acquisition itself can trigger heightened FDA scrutiny, particularly if the program has a prior clinical hold history, a pending safety review, or an unresolved agency correspondence thread. Mitigation requires reviewing all FDA correspondence in diligence, confirming no pending information requests exist, and ensuring the acquirer's regulatory team has a clear plan for assuming safety monitoring and reporting obligations from day one. Acquirers with limited prior FDA sponsor experience should retain a regulatory affairs firm immediately post-signing to conduct a gap assessment.
Does a sponsor change require updated patient consent forms at all active sites?
The obligation to update patient consent forms following a sponsor change depends on the nature of the change and the IRB's determination of whether it constitutes a modification requiring re-consent. Where the sponsor entity changes substantially, most IRBs will require at minimum an amended consent form identifying the new sponsor. Whether enrolled participants must affirmatively re-consent, versus having the updated form apply only to new enrollees, is a site-level and IRB-level determination. Acquirers should not assume that re-consent is unnecessary simply because the protocol remains unchanged. From a regulatory risk standpoint, having outdated consent forms identifying a dissolved or transferred entity as sponsor creates documentation deficiencies that FDA inspectors routinely cite. Counsel should build a consent form amendment workflow into the post-closing integration plan and assign responsibility before closing.
How is DSMB continuity managed across a clinical acquisition, and what are the legal risks?
A data safety monitoring board operates under a charter that defines its composition, meeting frequency, and authority to recommend trial modification or termination. The DSMB charter is a contractual document, and its members serve under individual consulting agreements with the original sponsor. When the sponsor changes, those consulting agreements do not automatically transfer, and DSMB members may decline continuation under a new sponsor entity. Acquirers must review all DSMB charters and member agreements in diligence, assess whether members are willing to continue, and determine whether the acquirer's legal entity satisfies any charter requirements regarding sponsor qualifications. A DSMB that does not convene on schedule creates a protocol deviation and, if a scheduled safety review is missed, potentially a reportable event. Ensuring DSMB continuity is part of the safety infrastructure transfer and should be addressed in the transition services agreement.
What is the risk that an acquirer's protocol amendments post-closing will trigger FDA review or enrollment delays?
Any protocol change that affects subject safety, trial objectives, endpoints, or the risk-benefit profile requires FDA notification and, depending on the nature of the change, a protocol amendment submission. Post-acquisition, acquirers sometimes seek to modify trial design to align the program with their portfolio or to incorporate newer endpoints based on scientific developments. Even changes that appear operationally minor may require a protocol amendment submitted as a safety report or IND amendment, and FDA has 30 days to place the trial on clinical hold after receiving a protocol amendment. Acquirers should evaluate any planned protocol changes before closing, model the regulatory pathway for each change, and understand whether changes are likely to trigger hold review. Changes that affect statistical analysis plans require additional coordination with the trial's biostatistician and may affect existing agreements with CROs and data management vendors.
Evaluating a Clinical-Stage Acquisition
Clinical trial transfers require coordination across regulatory counsel, clinical operations, pharmacovigilance, and manufacturing. Acquisition Stars advises on the full spectrum of clinical diligence and sponsor transfer mechanics. Submit your transaction details for a confidential assessment.
Related Practice Areas
Our attorneys handle M&A transactions and securities matters nationwide. Alex Lubyansky leads every engagement personally.